Preliminary evaluation of a new protocol for the actino-therapeutical treatment of uterine cervix carcinoma in stages II and III.
This study concerns 89 patients affected by uterine cervicocarcinoma at stage II or III, hospitalized at the Obstetric and Gynecological Clinic of Genoa University and subjected to transcutaneous (cobalt) and intracavitary (cesium137) actinotherapy. One year after the treatment end, the Authors observed and compared post-actinic troubles in a group of patients who had undergone a classic actinic treatment and in those subjected to a new therapeutical protocol based on dose fractionation. The latter showed a higher incidence of immediate troubles, but a lower percentage of cerviconeoplasia persistence.